DarioHealth Corp

NASDAQ DRIO

Data sourced from

and

Download Data

DarioHealth Corp Accounts Receivable Turnover Ratio 2 year CAGR for the year ending December 31, 2023: -27.86%

DarioHealth Corp Accounts Receivable Turnover Ratio 2 year CAGR is -27.86% for the year ending December 31, 2023, a -319.05% change year over year. The accounts receivable turnover ratio measures the efficiency of a company in collecting payments from its customers. It is calculated by dividing the company's revenue by its accounts receivable. This ratio provides insight into how quickly a company collects outstanding funds owed to it. A higher turnover ratio implies that the company efficiently converts credit sales into cash, while a lower ratio may indicate delays in collecting payments or potential issues with credit management. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

DarioHealth Corp Accounts Receivable Turnover Ratio for the year ending December 31, 2022 was 3.87, a -66.27% change year over year.
DarioHealth Corp Accounts Receivable Turnover Ratio for the year ending December 31, 2021 was 11.49, a 158.33% change year over year.
DarioHealth Corp Accounts Receivable Turnover Ratio for the year ending December 31, 2020 was 4.45, a -58.12% change year over year.
DarioHealth Corp Accounts Receivable Turnover Ratio for the year ending December 31, 2019 was 10.62, a -66.40% change year over year.

NASDAQ: DRIO

DarioHealth Corp

CEO	Mr. Erez Raphael
IPO Date	Oct. 6, 2014
Location	United States
Headquarters	18 West 18th Street, New York, NY, United States, 10011
Employees	276
Sector	Healthcare
Industry	Health information services

Description

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Key trends